T Cell News and Research

Latest T Cell News and Research

Scientists discover mechanism of herpes virus cell entry machinery

The mechanism by which a herpes virus invades cells has remained a mystery to scientists, but now research from Tufts University and the University of Pennsylvania reveals the unusual structure of a key member of the protein complex that allows a herpes virus to invade cells.The new map details an essential piece of the herpes virus "cell-entry machinery," providing scientists with a new target for antiviral drugs.

27 Jul 2010

Study analyses anesthetic effects on surgical site infections

A study appearing in the August 2010 issue of Anesthesiology found that patients receiving a total hip or knee replacement in Taiwan had a higher incidence of surgical site infections (SSIs) when general anesthesia was administered for the operation than when the same procedures were performed under epidural/spinal (regional) anesthesia.

27 Jul 2010

New drug for type 2 diabetes, Effect of insulin on bones

In a groundbreaking finding, a new medicine Galvus (vildagliptin) has been created for people with type 2 diabetes that would lower blood glucose levels without the side effects of other medications.

26 Jul 2010

CPC partners with CU School of Medicine on stem cell research

A major research company with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient.

26 Jul 2010

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange reported today that a significant decrease in HCV viral load was detected in 3 patients with liver cancer who are treated daily orally with CF102. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). The results announced today relate to data which came out of a Phase 1/2 clinical trial of CF102 in the treatment of patients with advanced HCC.

26 Jul 2010

Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.

26 Jul 2010

FDA grants Biovest's BiovaxID vaccine Orphan Drug Designation for mantle cell lymphoma

Biovest International, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest's personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma. Mantle cell lymphoma is an aggressive and lethal B-cell blood cancer for which there is no current consensus standard-of-care.

26 Jul 2010

Boston Scientific launches Neuroform EZ Stent System

Boston Scientific Corporation today announced the U.S. and European launches of the Neuroform EZ™ Stent System, its fourth-generation intracranial aneurysm stent system designed for use in conjunction with endovascular coiling to treat wide-necked aneurysms. The Company plans to launch the product immediately in both markets.

26 Jul 2010

AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc.. The milestone payment resulted from AVEO's recent initiation of a Phase 2 clinical trial to evaluate its AV-299 antibody for the treatment of non-small cell lung cancer. AV-299 is a humanized antibody to hepatocyte growth factor (HGF).

26 Jul 2010

Researchers discover potential method for neurodegenerative disease detection

New investigations, initiated by research workers at CIC bioGUNE and led by Dr. Aitor Hierro, have opened possibilities for making progress in the knowledge and prediction of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), according to the journal of The Proceedings of the National Academy of Sciences of the United States of America.This study opens the possibility of research in humans to detect this pathology before the symptoms arise.

26 Jul 2010

First Edition: July 26, 2010

Today's headlines include news about the politics of implementing the new health reform law as well as the ADA's 20th anniversary.

26 Jul 2010

Axela acquires Xceed Molecular

Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.

26 Jul 2010

Mismanagement of diabetes leads to fatal accident

One of the worst case scenarios that can happen to a diabetic is if he or she falls into a hypoglycemic coma. This is caused by a severe deficiency in glucose levels found in the blood which causes the brain to seek other energy sources at the same time shutting down other important body functions. If treatment is delayed or neglected by the diabetic person, such a coma can cause not only loss of consciousness but also irreversible brain damage and death.

26 Jul 2010

Glioblastomas patients with affected stem cell niche experience progression-free survival

Patients with deadly glioblastomas who received high doses of radiation that hit a portion of the brain that harbors neural stem cells had double the progression-free survival time as patients who had lower doses or no radiation targeting the area, a study from the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center has found.

26 Jul 2010

Neu5Gc in drugs provokes strong immune response

Researchers at the University of California, San Diego School of Medicine have discovered that a kind of sugar molecule common to chimpanzees, gorillas and other mammals but not found in humans provokes a strong immune response in some people, likely worsening conditions in which chronic inflammation is a major issue.

26 Jul 2010

Cell Therapeutics agrees to sell 4,060 shares of Series 6 preferred stock

Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $4.06 million of securities to an accredited investor in a private offering pursuant to Section 4(2) of the Securities Act of 1933, as amended. The securities consist of 4,060 shares of Series 6 preferred stock, no par value per share, together with warrants to purchase an aggregate of 5.8 million shares of common stock (the "Series 6 Financing"). The offering is scheduled to close on or about July 27, 2010, subject to the satisfaction of customary closing conditions.

26 Jul 2010

Gamma-tocotrienol suppresses colony formation of cancer stem cells: Research

Scientists from Singapore, Australia and Hong Kong have found that gamma-tocotrienol is potent in killing prostate cancer stem cells. This small group of cells is responsible for the initiation of prostate cancer and is resistant to conventional chemotherapy drugs. It causes relapses in the cancer by producing new chemo-resistant cancer cells. Gamma-tocotrienol is a member of the Vitamin E family and is derived naturally from palm oil.

26 Jul 2010

Inhibiting fatty acid synthase can reduce atherosclerosis: Study

Scientists at Washington University School of Medicine in St. Louis have found a way to significantly reduce atherosclerosis in mice that does not involve lowering cholesterol levels or eliminating other obesity-related problems.

26 Jul 2010

Experimental treatment for sickle cell disease enters Phase 3 clinical trials

An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO announced today.

26 Jul 2010

Scientists study Legionella's reprogramming on cells for survival, propagation

When it infects the lungs, the Legionnaire's bacterium Legionella pneumophila causes acute pneumonia. The pathogen's modus operandi is particularly ingenious: it infiltrates deliberately into cells of the human immune system and injects a host of proteins which then interfere in the normal cellular processes. Scientists from the Max Planck Institute of Molecular Physiology in Dortmund have now discovered how Legionella reprogrammes the cells to ensure its own survival and to propagate. They examined a protein used by the pathogen to divert the material transport within the cells for its own purposes.

26 Jul 2010